INTRODUCTION
============

Iron deficiency in early life adversely affects the growth and functioning of multiple organ systems.^[@nuz051-B1]^ The effects of iron deficiency on the developing brain are permanent and life-altering.^[@nuz051-B2],[@nuz051-B3]^ Preterm infants are deprived of the significant iron accretion that occurs in the third trimester of pregnancy and have reduced iron stores at birth compared with term infants.^[@nuz051-B4],[@nuz051-B5]^ Pregnancy complications, including gestational diabetes mellitus and fetal growth restriction, as well as maternal lifestyle factors such as smoking and obesity, also compromise infant iron stores.^[@nuz051-B6],[@nuz051-B7]^ Apart from the considerable impact of preterm birth itself, infants delivered preterm are at high risk of iron deficiency owing to the increased postnatal iron required to facilitate rapid growth and an earlier onset of erythropoiesis, which occurs 1--3 months earlier than in term infants.^[@nuz051-B8],[@nuz051-B9]^

Iron supplementation is recommended for preterm infants, although extreme caution is warranted, as the potential risk of iron overload is high. High iron doses from supplementation or blood transfusions can result in excess iron, leading to free circulating Fe^2+^ ions, which contribute to the production of reactive oxygen species that can affect sensitive organ systems, such as the heart, liver, pancreas, and developing brain.^[@nuz051-B10]^ Therefore, a balance in the provision of adequate iron is required to ensure optimal growth and development without contributing to iron overload.

To achieve this balance, international intake recommendations for enteral iron in preterm infants are 2--3 mg/kg/d from the age of 2--6 weeks until at least 6--12 months.^[@nuz051-B11],[@nuz051-B12]^ Higher iron doses (\>5 mg/kg/d) are only recommended for infants who are receiving erythropoietin treatment or for those that have experienced significant, uncompensated blood losses.^[@nuz051-B11]^ These recommendations, made in 2010, were based on a limited evidence basis, with significant heterogeneity in trial design and iron treatment doses among studies that primarily focused on the effects of supplementation in relation to hematological parameters. Systematic reviews in 2012 highlighted the lack of evidence regarding the effect of iron supplementation on functional health outcomes, particularly long-term growth and neurological development.^[@nuz051-B13],[@nuz051-B14]^

Following the 2010 recommendations and 2012 reviews, the availability of relevant intervention studies has increased. Therefore, the primary objective of the present work was to perform an updated systematic review to examine the effect of enteral iron supplementation on health outcomes in preterm and low-birth-weight (LBW, \<2500 g) infants. The main health outcomes of interest were iron status, growth, and neurological development. A secondary objective was to investigate associations between supplementation and adverse clinical outcomes.

METHODS
=======

The protocol for this systematic review was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered prospectively with PROSPERO (CRD42018085214).

Search strategy
---------------

The PubMed/Medline and Cochrane Library databases were searched up to October 31, 2018. A structured search strategy was devised, incorporating the Medical Subject Headings (MeSH) search terms "Infant, Low Birth Weight," "Infant, Extremely Low Birth Weight," "Infant, Very Low Birth Weight," "Infant, Premature," "Infant, Extremely Premature," "Premature Birth" or text words "preterm," "premature" AND MeSH terms "Iron," "Iron, Dietary," "ferrous" or text words "iron intake," "iron supplementation," "iron supplements," "ferrous sulphate/fumarate/sulfate," "dietary iron intake." Eligible studies were limited to English language articles only. The bibliographies of identified studies and key review (narrative and systematic/meta-analyses) articles were searched manually and incorporated into the current review in accordance with the eligibility criteria. Clinical trial registries were also searched for ongoing or recently completed trials.

Eligibility criteria
--------------------

Studies in infants born premature (\<37 wk' gestation) or with a birth weight \<2500 g investigating the effect of enteral iron supplementation on health outcomes, including iron status, growth, neurological development, and adverse clinical outcomes, were eligible for inclusion ([Table 1](#nuz051-T1){ref-type="table"}). Studies in which enteral iron supplementation was provided with concurrent erythropoietin treatment were not eligible. Narrative reviews, case reports, comments, and editorials were also excluded.

###### 

PICOS criteria for inclusion of studies

  Criterion                                                                                                                                                                                                  Description
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Participants                                                                                                                                                                                               Infants born premature (\<37 wk' gestation) or with a birth weight \<2500 g
  Intervention                                                                                                                                                                                               Iron supplementation through the enteral route, ie, medicinal iron, infant formula, human milk fortifier
  Comparison                                                                                                                                                                                                 Different regimens of enteral iron supplementation, with respect to dose, duration, and timing of initiation of supplementation
  Outcomes                                                                                                                                                                                                   1\. [Iron status]{.ul} during and/or post the intervention period:
  a\) Indices reflecting *storage* iron (ferritin), *transport* iron (iron, transferrin, TIBC, transferrin saturation, soluble transferrin receptors), and *functional* iron (MCV, hematocrit, hemoglobin)   
  b\) Prevalence of iron deficiency, iron deficiency anemia, and iron overload (as defined by study investigators)                                                                                           
  2\. [Growth-related parameters]{.ul} during and/or post the intervention period, including weight, length, and head circumference                                                                          
  3\. Measures of [neurological development]{.ul} during and/or post the intervention period, assessed through standardized neurodevelopmental assessments performed at predefined time points               
  4\. Incidence of adverse [short-term clinical outcomes]{.ul} (including NEC, ROP, CLD, PVL, oxidative stress, and sepsis) as defined by study investigators during and/or post the intervention period     
  Study design                                                                                                                                                                                               Any intervention study, including RCTs and nonrandomized trials

*Abbreviations:* CLD, chronic lung disease; MCV, mean corpuscular volume; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; RCT, randomized controlled trial; ROP, retinopathy of prematurity; TIBC, total iron-binding capacity.

Data collection
---------------

Following removal of duplicates, the titles and abstracts of all records retrieved from the search were screened independently by two researchers (E.K.M. and M.E.K.) to assess compliance with the eligibility criteria. Following exclusion of unsuitable records, the full texts of the remaining records were evaluated by all authors and the final list of included papers was agreed upon following discussion.

Information on study design/methodology, participant characteristics (eg, gestational age \[GA\], birth weight \[BW\], feeding method), interventions (dose, duration, timing initiation, comparators), outcome assessments (type, timing), and main findings were extracted from each study using an internally piloted, standardized data collection form. The duration of supplementation was stratified into short-term (\<8 wk) and long-term (≥8 wk). To ensure uniformity, the iron supplementation dose was standardized to mg/kg/d, using the published mean birth weight as the body weight for this calculation. For trials of infant formula, an estimate of the daily intake of formula of 160 mL/kg/d was applied.^[@nuz051-B13]^

The risk of bias in study design was assessed independently by the reviewers using the criteria set out by the *Cochrane Handbook for Systematic Reviews of Interventions*.^[@nuz051-B15]^ These criteria were used to assess both randomized controlled trials (RCTs) and nonrandomized trials, and further assessment of the risk of selection bias was performed for the nonrandomized trials.

RESULTS
=======

Study selection
---------------

Following the database searches, 684 records were identified and 4 duplicates were removed ([Figure 1](#nuz051-F1){ref-type="fig"}). Of the 680 records screened, 559 were excluded, mainly owing to no reported outcome of interest or a focus on maternal supplementation. Following full-text review of the remaining records, 27 papers were eligible for inclusion in the systematic review.^[@nuz051-B16]^

![Flow diagram of the literature selection process.](nuz051f1){#nuz051-F1}

Study characteristics
---------------------

The 27 included articles, characterized in [Table 2](#nuz051-T2){ref-type="table"},[@nuz051-B16] were published between 1974 and 2018 (including 7 since 2012), and most studies were conducted in Europe and North America. In total, there were 18 RCTs, as 5 publications^[@nuz051-B16],[@nuz051-B17],^[@nuz051-B22] were derived from a single trial conducted in Sweden.^[@nuz051-B24]^ There were 4 nonrandomized interventions.^[@nuz051-B27],[@nuz051-B29],[@nuz051-B37],[@nuz051-B42]^ Ten RCTs were placebo-controlled trials involving iron supplementation vs no supplementation/human milk as placebo^[@nuz051-B19],[@nuz051-B21],[@nuz051-B24],[@nuz051-B25],[@nuz051-B30],[@nuz051-B31],[@nuz051-B35],[@nuz051-B36],[@nuz051-B38],[@nuz051-B41]^; 4 trials compared 2 or more iron doses^[@nuz051-B20],[@nuz051-B32],[@nuz051-B34],[@nuz051-B39]^; and 4 compared early (age ≤2 wk) to late (4--8 wk) initiation of supplementation.^[@nuz051-B18],[@nuz051-B28],[@nuz051-B33],[@nuz051-B40]^ The study by Steinmacher et al^[@nuz051-B26]^ is a follow-on to the trial described by Franz et al.^[@nuz051-B33]^ The intervention dose provided in most studies was 2--4 mg/kg/d, although doses of 6--24.2 mg/kg/d were also reported^[@nuz051-B20],[@nuz051-B27],[@nuz051-B29],[@nuz051-B36],[@nuz051-B38],[@nuz051-B42]^ and the duration of supplementation ranged from 1 week to 1 year.

###### 

Characteristics of the included studies examining the effects of enteral iron supplementation on health outcomes in preterm and low-birth-weight infants

  Reference (country)                                       Eligibility                    Sample size[^a^](#tblfn2){ref-type="table-fn"}   Enteral iron dose                                                                                              Age when iron supplementation was initiated[@nuz051-B2]   Duration of intervention           Follow-up ages and outcomes[^b^](#tblfn3){ref-type="table-fn"}
  --------------------------------------------------------- ------------------------------ ------------------------------------------------ -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------
  Berglund et al (2018)[@nuz051-B16] (Sweden)               BW: 2000--2500 g               C: 73T1: 60T2: 72                                C: placeboT1: 1 mg/kg/dT2: 2 mg/kg/d                                                                           6 wk                                                      4.5 mo                             Follow-up: 7 yNeurological development
  Berglund et al (2015)[@nuz051-B17] (Sweden)               BW: 2000--2500 g               C: 77T1: 70T2: 74                                C: placeboT1: 1 mg/kg/dT2: 2 mg/kg/d                                                                           6 wk                                                      4.5 mo                             Follow-up: 12 mo, 3.5 yIndices: hemoglobin, MCV, ferritin, transferrin, iron, transferrin saturation, transferrin receptorGrowth
  Joy et al (2014)[@nuz051-B18] (India)                     GA: \<37 wkBW: 1000--1500 g    EI: 46LI: 47                                     Both groups 2 mg/kg/d                                                                                          EI: 2 wkLI: 6 wk                                          EI: 10 wkLI: 6 wk                  Follow-up: 2, 6, 12 wkIndices: ferritin, hemoglobinGrowthNeurological development adverse outcomes
  van de Lagemaat et al (2014)[@nuz051-B19] (Netherlands)   GA: ≤32 wkBW: ≤1500 g          IFF: 92HM: 46                                    Iron formula: ∼1.1--2.7 mg/kg/dHM: ∼0.8--1.4 mg/kg/d                                                           Term age                                                  6 mo                               Follow-up: term, 3, 6 mo' post termIndices: hemoglobin, hematocrit, MCV, ferritinGrowth
  Miller et al (2013)[@nuz051-B20] (USA)                    GA: 27--30 wk                  C: 40T: 41                                       C: 2.2 mg/kg/dT: range 3--12 mg/kg/d (ave. 10.4 mg/kg/d) dependent on ZnPP/H                                   \>1 wk (average age ∼ 3 wk)                               3 wk                               Follow-up: 6, 24 mo CAIndices: ferritin, hematocritGrowthNeurological development
  Taylor and Kennedy (2013)[@nuz051-B21] (USA)              BW: \<1500 g                   C: 74T: 76                                       C: no additional ironT: 2 mg/kg/d                                                                              Range: 6--49 d (\<32 wk PMA)                              4--5 wk                            Follow-up: 36 wk PMA/hospital dischargeIndices: hematocritGrowthAdverse outcomes
  Berglund et al (2013)^[@nuz051-B22]^ (Sweden)             BW: 2000--2500 g               C: 77 (3.5-y C: 95)T1: 70T2: 77                  C: placeboT1: 1 mg/kg/dT2: 2 mg/kg/d                                                                           6 wk                                                      4.5 mo                             Follow-up: 3.5 yNeurological development
  Berglund et al (2011)[@nuz051-B23] (Sweden)               BW: 2000--2500 g               C: 74T1: 72T2: 72                                C: placeboT1: 1 mg/kg/dT2: 2 mg/kg/d                                                                           6 wk                                                      4.5 mo                             Follow-up: 6 moNeurological development
  Berglund et al (2010)[@nuz051-B24] (Sweden)               BW: 2000--2500 g               C: 83T1: 78T2: 82                                C: placeboT1: 1 mg/kg/dT2: 2 mg/kg/d                                                                           6 wk                                                      4.5 mo                             Follow-up: 12, 19 wk, 6 moIndices: hemoglobin, MCV, ferritin, transferrin, iron, transferrin saturation, transferrin receptorGrowthAdverse outcomes
  Sankar et al (2009)[@nuz051-B25] (India)                  BW: \<1500 g                   C: 24T: 22                                       C: no iron supplementsT: 3--4 mg/kg/d                                                                          14 d                                                      6--7 wk                            Follow-up: 60 dIndices: ferritin, hemoglobin, hematocritGrowthAdverse outcomes
  Steinmacher et al (2007)[@nuz051-B26] (Germany)           BW: \<1301 g                   EI: 90LI: 74                                     EI: 2--4 mg/kg/dLI: 2 mg/kg/d                                                                                  EI: \>7 dLI: 61 d                                         NR                                 Follow-up: 5 y CANeurological development
  Braekke et al (2007)[@nuz051-B27] (Norway)                BW: \<1500 gGA: \<32 wk        21                                               Median dose: 9.4 mg/kg/d                                                                                       6 wk                                                      1 wk                               Follow-up: 7 wkIndices: hemoglobin, MCV, iron, ferritin, transferrin saturationAdverse outcomes
  Arnon et al (2007)[@nuz051-B28] (Israel)                  GA: ≤32 wk                     2-wk: 324-wk: 36                                 Both groups 5 mg/kg/d                                                                                          2 wk4 wk                                                  4--6 wk (to 8 wk of age)           Follow-up: 2, 4, 8 wkIndices: hemoglobin, iron, ferritin, soluble transferrin receptorAdverse outcomes
  Miller et al (2006)[@nuz051-B29] (USA)                    GA: 24--32 wk                  C: 16T: 16                                       C: no iron supplementsT: range 3--12 mg/kg/d (ave. 7 mg/kg/d) dependent on ZnPP/H                              Range: 7--60 d                                            2--3 wk                            Follow-up: 27--80 d (for 2--3 wk)Indices: ferritin, iron, total iron-binding capacity, transferrin receptorsAdverse outcomes
  Aggarwal et al (2005)^[@nuz051-B30]^ (India)              BW: \<2500 gGA: ≥37 wk         C: 30T: 32                                       C: placeboT: 3 mg/kg/d                                                                                         Range: 50--80 d                                           8 wk                               Follow-up: 4, 8 wkIndices: hemoglobin, ferritinGrowth
  Berseth et al (2004)^[@nuz051-B31]^ (USA)                 BW: ≤1500 gGA: ≤33 wk          C: 85T: 96                                       C HM fortifier: ∼0.6 mg/kg/dT HM fortifier: ∼2.4 mg/kg/d                                                       Range: 13--16 d                                           28 d                               Follow-up: study day 28/hospital dischargeIndices: hematocrit, ferritinGrowthAdverse outcomes
  Friel et al (2001)^[@nuz051-B32]^ (Canada)                BW: \<2500 g                   Normal: 29High: 29                               Normal iron formula: ∼2.1 mg/kg/dHigh iron formula: ∼3.4 mg/kg/d                                               mean: 32-wk GA (receiving full enteral feeds)             1 year                             Follow-up: 3, 6, 9, 12 mo CAIndices: hemoglobin, hematocrit, ferritin, transferrinGrowthNeurological development adverse outcomes
  Franz et al (2000)^[@nuz051-B33]^ (Germany)               BW: \<1301 g                   EI: 68LI: 65                                     EI: 2--4 mg/kg/dLI: 2 mg/kg/d                                                                                  EI: \>7 dLI: 61 d                                         NR                                 Follow-up: 61 dIndices: ferritin, transferrin, iron, MCV
  Griffin et al (1999)^[@nuz051-B34]^ (UK)                  GA: ≤32 wkBW: ≤1750 g          A: 29B: 34C: 15                                  A: preterm formula ∼1.5 mg/kg/dB: term formula ∼0.8 mg/kg/dC: preterm formula to term age, then term formula   35--37 d                                                  6 mo                               Follow-up: 1, 2, 3, 4, 5, 6 mo CAIndices: hemoglobin, ferritin
  Hall et al (1993)^[@nuz051-B35]^ (USA)                    BW: \<1800 gGA: \<35 wk        High: 20Low: 23HM: 13                            High-iron formula: ∼2.4 mg/kg/dLow-iron formula: ∼0.5 mg/kg/dHM: ∼0.3 mg/kg/d                                  8--10 d                                                   34--44 d (to hospital discharge)   Follow-up: discharge, 2, 4, 8, 12 wk PDIndices: hemoglobin, hematocrit, ferritin, transferrin, iron, MCVGrowth
  Barclay et al (1991)^[@nuz051-B36]^ (UK)                  BW: \<2500 g                   55                                               High iron: ∼7.1 mg/kg/dLow iron: ∼3.6 mg/kg/dNo iron: no additional iron                                       28 d                                                      16 wk                              Follow-up: 8, 12, 20 wkIndices: hemoglobin, MCV, ferritinGrowthAdverse outcomes
  Iwai et al (1986)^[@nuz051-B37]^ (Japan)                  BW: 1000--2499 g               HM: 15IFF: 30                                    HM: all infants received since birthIron formula: ∼1.3 mg/kg/d (given from 3 mo)                               3 mo                                                      IFF for 3 mo                       Follow-up: 1 week, 1, 2, 3, 4, 5, 6 moIndices: hemoglobin, ferritin, iron, iron-binding capacity, MCV
  Halliday et al (1983)^[@nuz051-B38]^ (UK)                 GA: 28--36 wk                  A: 16B: 17C: 16                                  A: 6 mg/kg/dB: placeboC: placebo to 8 wk, then 6 mg/kg/d                                                       7 d                                                       1 y                                Follow-up: 3, 6, 9, 12, 18, 24, 36, 54 wkIndices: hemoglobin, iron, transferrin, ferritin
  Rudolph et al (1981)^[@nuz051-B39]^ (USA)                 GA: ≤32 wkBW: 1001--1600 g     A: 6A1: 7B1: 5                                   A: standard formula (trace iron)A1: formula ∼1.9 mg/kg/dB1: soy-based formula ∼1.9 mg/kg/d                     5--6 d                                                    5 wk                               Follow-up: 1, 2, 3, 4, 5, 6 wkIndices: hemoglobin, hematocrit
  Jansson et al (1979)^[@nuz051-B40]^ (Sweden)              GA: ≤35 wkBW: ≤2000 g          A: 15B: 13                                       A: 2--3 mg/kg/dB: 2--3 mg/kg/d                                                                                 A: 3 wkB: 2 mo                                            4--5 mo (to 6 mo of age)           Follow-up: 1--2 d, 8--10 wk, 6 moIndices: hemoglobin, ferritin
  Lundstrom et al (1977)^[@nuz051-B41]^ (Finland)           BW: 1050--2000 g               T: 40C: 50                                       T: 2 mg/kg/dC: no additional iron                                                                              2 wk                                                      5.5 mo                             Follow-up: monthly to 6 moIndices: hemoglobin, iron, iron-binding capacity, ferritin
  Brozovic et al (1974)^[@nuz051-B42]^ (UK)                 GA: 29--37 wkBW: 920--1870 g   47                                               24.2 mg/kg/d                                                                                                   5 wk                                                      8 mo                               Follow-up: 3, 6, 9 moIndices: hemoglobin, iron, transferrin saturation, total iron-binding capacity

Sample size included in data analysis.

Chronological age, unless otherwise stated.

*Abbreviations:* BW, birth weight; C, control group; CA, corrected age; CRP, C-reactive protein; EI, early intervention; GA, gestational age; HM, human milk; IFF, iron-fortified formula; LI, late intervention; MCV, mean corpuscular volume; NR, not reported; PD, post discharge; PMA, postmenstrual age; RBC, red blood cells; RDW, red blood cell distribution width; T, treatment group; ZnPP/H, zinc protoporphyrin to heme ratio.

Outcomes from the 27 articles analyzed were described individually because, although there were 22 individual trials, each paper assessed health outcomes independently. This is a challenging and vulnerable population to study. Although the overall study quality was poor to fair, some of the recent studies were of high quality ([Table 3](#nuz051-T3){ref-type="table"}[@nuz051-B16]). The main source of bias in the RCTs was a lack of allocation concealment during the intervention (12/18 RCTs), although most did employ an appropriate method of randomization (16/18). Incomplete outcome data was another limitation of many of the papers, with significant, but understandable, attrition of participants in studies involving long-term follow-up. Given the large degree of heterogeneity in study design, a quantitative comparison or meta-analysis was inappropriate and not feasible. Particular limitations that precluded such an analysis were the variability in participant characteristics with respect to GA and BW; differences in intervention doses, timing, and duration of supplementation; and variability in both outcomes and timing and methods of outcome assessment.

###### 

Assessment of risk of bias in the studies reported on in the 27 articles included in the present review

  Reference                                                                 Random sequence generation   Allocation concealment   Blinding of participants/ personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting
  ------------------------------------------------------------------------- ---------------------------- ------------------------ ------------------------------------- -------------------------------- ------------------------- ---------------------
  Berglund et al (2018)[@nuz051-B16]                                        Low risk                     Low risk                 Low risk                              Low risk                         High risk                 Low risk
  Berglund et al (2015)[@nuz051-B17]                                        Low risk                     Low risk                 Low risk                              Low risk                         Low risk                  Low risk
  Joy et al (2014)[@nuz051-B18]                                             Low risk                     Low risk                 High risk                             Low risk                         Low risk                  Low risk
  van de Lagemaat et al (2014)[@nuz051-B19]                                 Low risk                     Low risk                 Low risk                              Low risk                         Low risk                  Low risk
  Miller (2013)^[@nuz051-B20]^                                              Low risk                     Low risk                 Low risk                              Low risk                         High risk                 Low risk
  Taylor and Kennedy (2013)^[@nuz051-B21]^                                  Low risk                     Low risk                 Low risk                              Low risk                         Low risk                  Low risk
  Berglund et al (2013)^[@nuz051-B22]^                                      Low risk                     Low risk                 Low risk                              Low risk                         Low risk                  Low risk
  Berglund et al (2011)^[@nuz051-B23]^                                      Low risk                     Low risk                 Low risk                              Low risk                         High risk                 Low risk
  Berglund et al (2010)^[@nuz051-B24]^                                      Low risk                     Low risk                 Low risk                              Low risk                         Low risk                  Low risk
  Sankar et al. (2009)^[@nuz051-B25]^                                       Low risk                     Low risk                 High risk                             Low risk                         Low risk                  Low risk
  Steinmacher et al (2007)^[@nuz051-B26]^                                   Low risk                     Unclear                  Low risk                              Low risk                         Low risk                  Low risk
  Braekke et al (2007)^[@nuz051-B27]^[^a^](#tblfn5){ref-type="table-fn"}    High risk                    High risk                High risk                             High risk                        Low risk                  Low risk
  Arnon et al (2007)^[@nuz051-B28]^                                         Low risk                     Unclear                  Low risk                              Low risk                         High risk                 Low risk
  Miller et al (2006)^[@nuz051-B29]^[^a^](#tblfn5){ref-type="table-fn"}     High risk                    High risk                High risk                             High risk                        Low risk                  Low risk
  Aggarwal et al (2005)^[@nuz051-B30]^                                      Low risk                     Unclear                  Low risk                              Low risk                         High risk                 Low risk
  Berseth et al (2004)^[@nuz051-B31]^                                       Low risk                     Unclear                  Low risk                              Low risk                         High risk                 Low risk
  Friel et al (2001)^[@nuz051-B32]^                                         Low risk                     Unclear                  Low risk                              Low risk                         High risk                 Low risk
  Franz et al (2000)^[@nuz051-B33]^                                         Low risk                     Unclear                  Low risk                              Low risk                         High risk                 Low risk
  Griffin et al (1999)^[@nuz051-B34]^                                       Low risk                     Unclear                  Low risk                              Low risk                         Low risk                  Low risk
  Hall et al (1993)^[@nuz051-B35]^                                          Low risk                     Unclear                  Low risk                              Low risk                         High risk                 Low risk
  Barclay et al (1991)^[@nuz051-B36]^                                       Unclear                      Unclear                  Unclear                               Unclear                          Low risk                  Low risk
  Iwai et al (1986)^[@nuz051-B37]a^                                         High risk                    High risk                High risk                             High risk                        Unclear                   Low risk
  Halliday et al (1983)^[@nuz051-B38]^                                      Low risk                     Unclear                  Low risk                              Unclear                          Unclear                   Low risk
  Rudolph et al (1981)^[@nuz051-B39]^                                       Low risk                     Unclear                  High risk                             High risk                        High risk                 Low risk
  Jansson et al (1979)^[@nuz051-B40]^                                       Low risk                     Unclear                  Unclear                               Unclear                          Low risk                  Low risk
  Lundstrom et al (1977)^[@nuz051-B41]^                                     High risk                    High risk                Unclear                               Unclear                          Low risk                  Low risk
  Brozovic et al (1974)^[@nuz051-B42]^[^a^](#tblfn5){ref-type="table-fn"}   High risk                    High risk                High risk                             High risk                        Low risk                  Low risk

Nonrandomized trial -- risk of selection bias also assessed in these studies.

Effects of enteral iron supplementation
---------------------------------------

### Iron status indices

The effect of supplementation on iron status indices was assessed in 23 papers.[@nuz051-B17]^,[@nuz051-B24],[@nuz051-B25],^[@nuz051-B27] In 8 trials, duration of supplementation was \<8 weeks, and in 11 trials duration of supplementation was ≥8 weeks, while another 4 trials investigated the timing of supplementation initiation. While 2 studies,^[@nuz051-B27],[@nuz051-B35]^ including a small nonrandomized trial of high-dose iron (9.4 mg/kg/d) in very-low-birth-weight (VLBW, \<1500 g) infants,^[@nuz051-B27]^ observed a small effect of short-term supplementation on iron indices, the other studies on short-term supplementation reported no effect.^[@nuz051-B20],[@nuz051-B21],[@nuz051-B25],[@nuz051-B29],[@nuz051-B31],[@nuz051-B39]^ Treatment with medicinal iron, formula, or human milk fortifier at 2--4 mg/kg/d was found to have no effect on ferritin, hematocrit, or hemoglobin concentrations in VLBW infants.^[@nuz051-B21],[@nuz051-B25],[@nuz051-B31],[@nuz051-B39]^ Additionally, high-dose (average 7--10 mg/kg/d) supplementation in infants born at less than 32 weeks' gestation had no effect on ferritin, iron, transferrin saturation, transferrin receptors, or total iron-binding capacity (TIBC).^[@nuz051-B20],[@nuz051-B29]^

Of the 11 studies in which duration of supplementation was ≥8 weeks, 8 reported an effect on iron status.^[@nuz051-B17],[@nuz051-B19],[@nuz051-B24],[@nuz051-B30],[@nuz051-B36],[@nuz051-B37],[@nuz051-B41],[@nuz051-B42]^ In marginally LBW infants, a dose of 2 mg/kg/d increased circulating iron, ferritin, transferrin saturation, transferrin receptors, mean corpuscular volume (MCV), and hemoglobin at 6 months compared to the placebo group.^[@nuz051-B24]^ Ferritin concentrations remained significantly higher at 12 months, but not at 3.5 years, in the marginally LBW infants compared with the placebo group.^[@nuz051-B17]^ Supplementation with high-dose (∼7.1 and 24.2 mg/kg/d) medicinal iron resulted in higher serum ferritin and iron concentrations.^[@nuz051-B36],[@nuz051-B42]^ Long-term formula interventions also reported beneficial effects on ferritin, MCV, and hemoglobin concentrations.^[@nuz051-B19],[@nuz051-B37]^ Three studies observed no effect with long-term supplementation,^[@nuz051-B32],[@nuz051-B34],[@nuz051-B38]^ including 2 dose-comparison formula interventions, where consumption of a higher-iron formula had no effect on ferritin, transferrin, hematocrit, or hemoglobin concentrations compared with a lower-iron formula.^[@nuz051-B32],[@nuz051-B34]^

Four studies examined the effect of early vs late initiation of supplementation on iron status.^[@nuz051-B18],[@nuz051-B28],[@nuz051-B33],[@nuz051-B40]^ Short-term interventions by Joy et al^[@nuz051-B18]^ and Arnon et al^[@nuz051-B28]^ reported higher ferritin, iron, transferrin receptors, and hemoglobin in infants initiated at 2 weeks vs 4--6 weeks of age. In the only long-term trial, no differences in ferritin or hemoglobin were observed between infants that received 2--3 mg/kg/d from the age of 3 weeks and those that received the same dose from 8 weeks.^[@nuz051-B40]^

### Prevalence of iron deficiency, iron deficiency anemia, and iron overload

Nine articles reported the effect of iron supplementation on the prevalence of iron deficiency or iron deficiency anemia.^[@nuz051-B17],[@nuz051-B19],[@nuz051-B24],^[@nuz051-B32]^,[@nuz051-B37],[@nuz051-B41]^ It is worth noting that no article reported on iron overload. In the only short-term intervention, treatment with a high-iron formula (∼2.4 mg/kg/d, delivering 15 mg/L) resulted in a lower prevalence of low serum ferritin (\<19 ng/mL) (32% in the high-iron vs 79% in the low-iron group) and anemia (hemoglobin \<9 g/dL) (26% vs 70%) than treatment with a low-iron formula (∼0.5 mg/kg/d, delivering 3 mg/L).^[@nuz051-B35]^ The prevalence of low ferritin among infants receiving fortified human milk (delivering 1.7 mg/L) was 23%, and 77% were anemic.

In 2 long-term RCTs looking at formula milk, a reduced incidence of iron deficiency was observed in the formula-fed groups compared to the human milk--fed groups.^[@nuz051-B19],[@nuz051-B37]^ Long-term medicinal iron supplementation was also associated with a reduced prevalence of iron deficiency and/or iron deficiency anemia.^[@nuz051-B17],[@nuz051-B24],[@nuz051-B33],[@nuz051-B41]^ Marginally LBW infants supplemented with 2 mg/kg/d had a lower prevalence of iron depletion, iron deficiency, and anemia at both 6 and 12 months than those in the placebo group.^[@nuz051-B17],[@nuz051-B24]^ Comparable findings were reported in an initiation timing trial; 15% of infants supplemented at ∼1 week of age had iron deficiency compared to 40% of those initiated at ∼8.5 weeks.^[@nuz051-B33]^

### Growth

Twelve papers investigated the effects of iron supplementation on growth-related parameters -- namely, weight, length, and head circumference.[@nuz051-B17]^,[@nuz051-B24],[@nuz051-B25],^[@nuz051-B30]^,[@nuz051-B35],[@nuz051-B36]^ In 6 short-term interventions, no effect of medicinal iron, formula, or fortifier on any growth-related parameters was observed.^[@nuz051-B18],[@nuz051-B20],[@nuz051-B21],[@nuz051-B25],[@nuz051-B31],[@nuz051-B35]^ In the only short-term intervention with long-term follow-up, high-dose (average 10.4 mg/kg/d) iron had no effect on weight, length, or head circumference up to 24 months corrected age (CA).^[@nuz051-B20]^ Six articles reported that long-term supplementation had no effect on growth,^[@nuz051-B17],[@nuz051-B19],[@nuz051-B24],[@nuz051-B30],[@nuz051-B32],[@nuz051-B36]^ including a high-dose (∼7.1 mg/kg/d) medicinal iron RCT in LBW infants.^[@nuz051-B36]^ Long-term supplementation of 1--2 mg/kg/d had no effect on long-term growth to 3.5 years of age in marginally LBW infants.^[@nuz051-B17],[@nuz051-B24]^

### Neurological development

Seven articles reported on studies that explored the effect of iron supplementation on neurological development, as summarized in [Table 4](#nuz051-T4){ref-type="table"}.^[@nuz051-B16],[@nuz051-B18],[@nuz051-B20],[@nuz051-B22],[@nuz051-B23],[@nuz051-B26],[@nuz051-B32]^ Short-term supplementation had no effect on neurological development in 2 RCTs,^[@nuz051-B18],[@nuz051-B20]^ including a high-dose (average 10.4 mg/kg/d) trial with outcomes assessed to 2 years of age.^[@nuz051-B20]^ In an initiation timing trial of 2--4 mg/kg/d, while no effect on cognition, motor function, visual impairment, or behavior was observed at 5 years CA, there was a trend towards benefit of early initiation; 35% of the late initiation group had an abnormal neurological examination result compared to 19% of the early initiation group.^[@nuz051-B26]^ While no effect of long-term supplementation on neurophysiological functioning -- assessed using auditory brainstem responses -- was observed at 6 months in a Swedish RCT in marginally LBW infants,^[@nuz051-B23]^ supplemented children had a significantly lower prevalence of behavioral problems than those in the placebo group (3% vs 13%, respectively) at 3.5 years^[@nuz051-B22]^ and had significantly lower scores in externalizing-type behaviors (aggression/attention seeking) at 7 years.^[@nuz051-B16]^

###### 

Effect of enteral iron supplementation on neurological development in preterm and low-birth-weight infants

  Reference                                                                                                                                                              Duration of intervention                                                                     Age at follow-up[^a^](#tblfn6){ref-type="table-fn"}  Outcome assessment                                  Main findings
  ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Berglund et al (2018)[@nuz051-B16]                                                                                                                                              4.5 mo                                                                                                      7 y                          Wechsler Scale of Intelligence                      No significant differences between treatment groups in Wechsler Scale or Five-to-Fifteen scores.
  Child Behavior Checklist                                                                                                                                                                                                                                                                                                                                                     
  Five-to-Fifteen questionnaire                                                                                 Children in placebo group had significantly higher Child Behavior Checklist scores for externalizing problems than did supplemented groups.                                                                                                                    
  Joy et al (2014)[@nuz051-B18]                                                                                                                                                  6--10 wk                                                                                                    12 wk                         Hammer-Smith neurological examination               No significant difference between treatment groups in prevalence of neurological deficits.
  Miller et al (2013)^[@nuz051-B20]^                                                                                                                                               3 wk                                                                                                 6 and 24 mo CA                     Bayley Scales of Infant Development (3rd Edition)   No significant difference between treatment groups in scores at 6 or 24 mo CA.
  Berglund et al (2013)^[@nuz051-B22]^                                                                                                                                            4.5 mo                                                                                                     3.5 y                         Wechsler Scale of Intelligence                      No significant difference between treatment groups on Wechsler Scale.
  Child Behavior Checklist                                                                              Significantly higher prevalence of Child Behavior Checklist total problem scores \> US subclinical cutoff in placebo group compared to supplemented groups.                                                                                                            
  Berglund et al (2011)^[@nuz051-B23]^                                                                                                                                            4.5 mo                                                                                                     6 mo                          Auditory brainstem responses                        No significant difference between treatment groups in auditory brainstem response wave V latencies.
  Central conduction time significantly higher in treatment group but not correlated to iron intake.                                                                                                                                                                                                                                                                           
  Steinmacher et al (2007)^[@nuz051-B26]^                                                                                                                                           NR                                                                                                      5 y CA                         Gross Motor Functioning Classification Scale        Significantly higher prevalence of abnormal results on standard neurological examination in late group compared to early group.
  Lincoln-Oseretsky Scale                                                                                                                     No significant differences between groups in any other developmental measures.                                                                                                                                                   
  Kaufman Assessment Battery                                                                                                                                                                                                                                                                                                                                                   
  Visual impairment                                                                                                                                                                                                                                                                                                                                                            
  Child Behavior Checklist                                                                                                                                                                                                                                                                                                                                                     
  Friel et al (2001)^[@nuz051-B32]^                                                                                                                                                 1 y                                                                                                3, 6, 9, 12 mo CA                   Griffiths Mental Development Assessment             No significant difference between treatment groups in assessment scores at any time point.

Chronological age, unless otherwise stated.

*Abbreviation:* CA, corrected age; NR, not reported.

### Adverse clinical outcomes

Nine articles reported the effect of supplementation on the incidence of short-term adverse clinical outcomes, including necrotizing enterocolitis, retinopathy of prematurity, chronic lung disease, periventricular leukomalacia, oxidative stress, and sepsis ([Table 5](#nuz051-T5){ref-type="table"}^[@nuz051-B18],[@nuz051-B21],[@nuz051-B25],^[@nuz051-B27]^,[@nuz051-B31],[@nuz051-B32],[@nuz051-B36]^). Short-term supplementation with medicinal iron or human milk fortifier at 2--4 mg/kg/d had no effect in 4 RCTs.^[@nuz051-B18],[@nuz051-B21],[@nuz051-B25],[@nuz051-B31]^ High-dose (≥5 mg/kg/d) iron for \<8 weeks also had no effect on adverse outcomes, including measures of oxidative stress, in 1 timing RCT and 2 nonrandomized trials.[@nuz051-B27]

###### 

Effect of enteral iron supplementation on incidence of adverse short-term clinical outcomes in preterm and low-birth-weight infants

  Reference                                  Necrotizing enterocolitis   Retinopathy of prematurity   Chronic lung disease   Periventricular leukomalacia   Oxidative stress                                   Sepsis
  ------------------------------------------ --------------------------- ---------------------------- ---------------------- ------------------------------ -------------------------------------------------- --------------
  Joy et al (2014)^[@nuz051-B18]^            No effect                   No effect                    Not reported           No effect                      Not reported                                       Not reported
  Taylor and Kennedy (2013)^[@nuz051-B21]^   No effect                   Not reported                 No effect              Not reported                   Not reported                                       No effect
  Sankar et al (2009)^[@nuz051-B25]^         No effect                   No effect                    No effect              No effect                      Not reported                                       No effect
  Braekke et al (2007)^[@nuz051-B27]^        Not reported                Not reported                 Not reported           Not reported                   No effect                                          Not reported
  Arnon et al (2007)^[@nuz051-B28]^          No effect                   No effect                    No effect              No effect                      Not reported                                       No effect
  Miller et al (2006)^[@nuz051-B29]^         Not reported                Not reported                 Not reported           Not reported                   No effect                                          Not reported
  Berseth et al (2004)^[@nuz051-B31]^        No effect                   Not reported                 Not reported           Not reported                   Not reported                                       No effect
  Friel et al (2001)^[@nuz051-B32]^          Not reported                Not reported                 Not reported           Not reported                   Glutathione peroxidase higher in high iron group   Not reported
  Barclay et al (1991)^[@nuz051-B36]^        Not reported                Not reported                 Not reported           Not reported                   Superoxide dismutase lower in high iron group      Not reported

Measures of antioxidant activity/oxidative stress were reported in 2 long-term RCTs.^[@nuz051-B32],[@nuz051-B36]^ Erythrocyte superoxide dismutase activity decreased in the high-iron (∼7.1 mg/kg/d) group during a 16-week RCT, with no changes observed in the low-iron (∼3.6 mg/kg/d) or no-iron groups, although no effect was seen with other markers of copper metabolism or plasma zinc.^[@nuz051-B36]^ In 1 year-long RCT, glutathione peroxidase activity was slightly higher in the high-iron formula (∼3.4 mg/kg/d) group than in the normal (∼2.1 mg/kg/d) formula group at study-end, but no differences in superoxide dismutase activity, malondialdehyde, or catalases were observed.^[@nuz051-B32]^

DISCUSSION
==========

This systematic review provides an important update on the evidence regarding the effect of enteral iron supplementation on health outcomes in preterm and LBW infants. Since the 2010 recommendations for preterm infants, an additional 8 papers have been published, based on 5 trials. Despite this new evidence, questions about the long-term health benefits or risks of enteral iron supplementation in preterm and LBW infants, over and above improved iron status, still remain.

Consistent with the evidence in term-born infants and children,^[@nuz051-B43],[@nuz051-B44]^ iron supplementation for ≥8 weeks appears to result in improved iron status in preterm and LBW infants, with ferritin and hemoglobin the most frequently reported indices. There is little to no benefit of short-term supplementation (\<8 wk) in this population. Worryingly, the long-term effect of supplementation remains unclear; only 1 trial, published in 2015, measured iron indices beyond 1 year of age.^[@nuz051-B17]^ Long-term supplementation was associated with a decreased prevalence of iron deficiency and anemia in preterm and LBW infants, although, only 9 of the articles in this review reported data on the prevalence of iron deficiency. The reporting of prevalence data enables meaningful comparisons across studies; investigating a supplementation effect on individual indices in isolation is of limited benefit in terms of understanding the clinical condition itself. However, to achieve this, the current uncertainty regarding the appropriate diagnostic criteria for iron deficiency in this population should be addressed as a matter of urgency.

A U-shaped curve of risk is associated with iron, as both deficiency and overload can lead to impaired health outcomes.^[@nuz051-B43],[@nuz051-B45]^ Excess iron has been associated with decreased growth, impaired cognitive development, and an increased risk of infection, with evidence also emerging of altered gut microbiota in infants and young children.^[@nuz051-B45],[@nuz051-B46]^ Preterm infants are particularly vulnerable to iron overload; however, the issue of overload was largely not addressed by the articles in this review. Further consideration of overload and its potential consequences in this vulnerable population is warranted, especially in very preterm infants who often receive multiple blood transfusions during their hospital stay.^[@nuz051-B47]^ As hemoglobin concentrations alone do not provide enough insight into the development of iron overload, clinical management should also include the routine measurement of ferritin concentrations, particularly during the inpatient period. This would facilitate the establishment of more personalized and tailored supplementation regimens; for example, in infants with elevated ferritin concentrations (\>300µg/L), supplementation could be delayed or ceased temporarily until their ferritin concentrations return to normal.^[@nuz051-B9],[@nuz051-B48]^ Further investigation into the suitability of other iron indices, such as transferrin receptors, in this population is also necessary.

While excess free iron has been postulated to play a role in the etiology of some neonatal diseases,[@nuz051-B49] this review found no reported evidence of an increased risk of necrotizing enterocolitis, retinopathy of prematurity, chronic lung disease, periventricular leukomalacia, or sepsis with supplementation. Two RCTs observed slight changes in oxidative stress markers following long-term supplementation, but the clinical significance of these changes are unclear as long-term follow-up was not implemented.^[@nuz051-B32],[@nuz051-B36]^ No other studies of high-dose supplementation reported adverse effects,^[@nuz051-B27]^ although it is important to note that the evidence to date is inadequate, particularly given the wide variability in the monitoring of adverse outcomes in trials, in both the frequency and type of clinical data collected. Trials need to include the systematic collection of adverse outcome data, thereby enabling an accurate assessment of the potential risks of supplementation, which is yet to be achieved.

Adverse effects of iron supplementation for growth in iron-replete infants and young children have been reported.^[@nuz051-B45]^ In this review, there was no evidence that short- or long-term iron supplementation had any adverse or beneficial effects on growth in preterm and LBW infants. There is still insufficient evidence regarding the effect on long-term growth: only 2 trials assessing growth-related parameters beyond the first year of life were published in the intervening years since the recommendations.^[@nuz051-B17],[@nuz051-B20]^ Most studies included measurements of weight, length, and head growth only, with actual or z-score changes in growth parameters reported by relatively few of the included articles. Moreover, the potential effect of iron supplementation on body composition in this population is yet to be investigated.

The evidence regarding the effect of iron supplementation on neurological development in preterm and LBW infants is limited. Only 7 articles reported on studies that evaluated neurological development; while 5 of these articles were published since the 2010 recommendations, 3 were based on the same trial in marginally LBW infants. There was no evidence of an effect of supplementation on cognition in preterm and LBW infants; however, long-term supplementation was suggested to have a positive effect on behavior, albeit only in that trial of marginally LBW infants.^[@nuz051-B16],[@nuz051-B22]^ The effect of supplementation in the most vulnerable infants, particularly those born very preterm or with a birth weight \<1500 g, is yet to be elucidated. This paucity of data, combined with the significant methodological differences in assessments, have made it difficult to draw meaningful conclusions in this review. Further, the difficulty in determining the effect of iron supplementation, above and beyond the potential effect of other comorbidities, is a significant challenge in this vulnerable population.

The extensive search strategy and prospective protocol registration are strengths of this review, although the search was limited to English language articles only. The generalizability of this review's findings is limited to high-resource settings, where the studies were predominately conducted.

While limited evidence was available on which to base the 2010 recommendations, this review has not identified sufficient quantities of appropriate, consistent evidence published since then to formulate revised recommendations from the perspectives of dosing or duration of supplementation. The substantial heterogeneity in trial design with respect to participant characteristics, intervention regimens, outcome assessments, and follow-up has limited study comparisons. In particular, the iron dose administered in trials conducted both pre and post the 2010 recommendations has been variable, making it difficult to truly assess the benefits or risks of higher doses. The most effective delivery method for iron in this population remains unclear, especially given the lack of consideration given by many investigators to the variability in iron concentration and bioavailability of different feeding methods. The significant difference in participants' underlying medical care is another challenge that is often unaccounted for, particularly with respect to placental transfusion methods, use of blood transfusions, nutritional management, or other nutrient supplementation.

CONCLUSION
==========

Long-term iron supplementation appears to result in improved iron status, coupled with a decrease in iron deficiency and anemia in preterm and LBW infants. No beneficial or adverse effects of supplementation on short-term growth outcomes have been reported. However, there remains a paucity of high-quality evidence on the effect of iron supplementation on other health outcomes, in particular with respect to long-term growth and neurological development. The potential adverse effects of supplementation, particularly the risk of iron overload, require further consideration.

The 2010 recommendations for enteral iron supplementation in preterm infants should continue to be implemented. However, adjustments in clinical practice should be carefully considered. Tailored supplementation regimens for individual patients, based on routine monitoring of iron status indices, particularly hemoglobin and ferritin, should be formulated for all hospitalized preterm and LBW infants, particularly those in receipt of multiple blood transfusions.

Advancement of this research field is necessary before the current recommendations can be updated. However, the ethical constraints of conducting a placebo-controlled trial in this vulnerable population group present a significant challenge. Therefore, well-designed, long-term, dose-response RCTs, comparing 2 or more iron doses and including a fortified human milk control group, are required to ascertain the optimal dose and delivery method for the provision of iron in preterm infants. Follow-up of short-, medium-, and long-term health outcomes is essential, while further consideration of the most vulnerable infants, particularly those born very preterm, is also needed.
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